Clinical Review for Power Plus
The Safety and Efficacy of Power Plus (poly-enzyme supplement) on Patients with Irritable Bowel Syndrome
This randomized, placebo-controlled, double-blind clinical trial on the efficacy and safety of Power Plus has been submitted the Journal of Clinical Nutrition and is pending publication. The purpose of the clinical study was to assess the efficacy this poly-enzyme supplement on patients with IBS (Irritable Bowel Syndrome).
Investigators (Hajjar et al) tested the effectiveness of this poly-enzyme supplement by assessing abdominal pain, bloating, constipation, diarrhea, and mucus with bowel movements. Moreover, a CBC (Complete Blood Count) was obtained for every participant.
Materials and methods
60 subjects from two centers underwent randomization and were divided into two groups to receive either the active investigational product (Power Plus) or a placebo with a non-active recipient. The duration of the study trial was 90 days. Patients were screened to meet the inclusion and exclusion criteria for the study protocol. Thereafter, three follow-up visits were scheduled at week 4, week 8, and week 12 to ascertain the subjects' symptoms and physical findings.
Power Plus demonstrated a significant improvement in reducing abdominal pain, bloating, constipation, diarrhea, and bowel mucus when compared to the placebo. The overall improvement registered an average of 74% for all markers assessed. Details of each marker tested will be provided in the publication of the trial. Noteworthy is that investigators found no evidence of adverse events from the ingestion of the investigational product.
Nasser Hajjar, MD, Internal Medicine, Gastroenterologist, American University of Beirut, Beirut, Lebanon
Mike Hung, MD, Ph.D., Internal Medicine, Gastroenterologist, Hubei Medical University, China.
Roger Patick, MD, Internal Medicine, Gastroenterologist, University of Montreal, Canada.
Charlie Khano, MD, Internal Medicine, Durango Medical Group, Denver, Colorado
Phillip Shinnick, D.C., Ph.D., Private Practice, NY, NY, The Research Institute of Global Physiology, Behavior and Treatment, INC., NY, NY
Cindy Maloore, Ph.D., Nutritionist, Private Practice, Santa Clara, CA
Carol Poppay, RN, Chief Nurse, Intel Corporation, Santa Clara, CA
The study was submitted to:
Journal of Therapeutics Gastrointestinal Research